Effects of AZD3480 on cognition in patients with mild-to-moderate alzheimer's disease: A phase IIb dose-finding study

Journal of Alzheimer's Disease

Volumn 24, Issue 2, 2011, Pages 363-374

  Frölich, Lutz ^a   Ashwood, Tim ^b   Nilsson, Jonas ^b   Eckerwall, Göran ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Alzheimer's disease; AZD3480; cognitive impairment; NNR agonist; randomized controlled trial

Indexed keywords

DONEPEZIL; ISPRONICLINE; PLACEBO;

AD ASSESSMENT SCALE COGNITIVE SUBSCALE; AD COOPERATIVE STUDY CLINICAL GLOBAL IMPRESSION OF CHANGE; ADULT; AGED; ALZHEIMER DISEASE; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE; CLINICAL ASSESSMENT TOOL; COGNITION; CONTROLLED STUDY; DIARRHEA; DISABILITY ASSESSMENT FOR DEMENTIA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NIGHTMARE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION; URINE INCONTINENCE; VOMITING; WITHDRAWAL SYNDROME;

EID: 79955627514     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2011-101554     Document Type: Article

References (41)

1. Cummings JL (2004) Alzheimer's disease. N Engl J Med351, 56-67.
2. Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1, CD005593.
3. McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev 2, CD003154.
4. Newhouse P, Potter A, Corwin J (1996) Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer's and Parkinson's disease. Drug Dev Res 38, 278-289. (Pubitemid 27034045)
5. Gotti C, Zoli M, Clementi F (2006) Brain nicotinic acetylcholinereceptors: native subtypes and their relevance. Trends Pharmacol Sci 27, 482-491. (Pubitemid 44251225)
6. Levin ED, McClernon FJ, Rezvani AH (2006) Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification and anatomic localization. Psychopharmacology 184, 523-539. (Pubitemid 43255869)
7. Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nasland J, Davis K, Gotti C, Clementi F, Tzartos S, Cohen O, Soreq H, Jaros E, Perry R, Ballard C, McKeith I, Court J (2000) Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 393, 215-222. (Pubitemid 30193419)
8. Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, Marks MJ, Collins AC, Leonard S (2000) Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23, 351-364.
9. Paterson D, Norberg A (2000) Neuronal nicotinic receptors in the human brain. ProgNeurobiol 61, 75-111. (Pubitemid 30100404)
10. Buccafusco JJ, Letchworth SR, Bencherif M, Lippiello PM (2005) Long-lasting cognitive improvement with nicotinicreceptoragonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol Sci 26, 352-360. (Pubitemid 40848496)
11. Bohme GA, Letchworth SR, Piot-Grosjean O, Gatto GJ, Obinu M-C, Caldwell WS, Laville M, Brunel P, Pellerin R, Leconte J-P, Genevois-Borella A, Dubedat P, Mazadier M, Pradier L, Bencherif L, Benavides J (2004) In vitro and in vivo characterization of TC-1827, a novel brain α4 ß2 nico-tinic receptor agonist with pro-cognitive activity. Drug Dev Res 62, 26-40. (Pubitemid 39458699)
12. Moore WC, Togo J, Smith JS, Doherty JJ, Johnson EC (2008) AZD3480, a selective α2/α4ß2 neuronal nicotinic agonist, reverses fimbria fornix lesion. Program No. 329.4/C55, Page 167, 2008 Neuroscience Meeting Planner, Washington, DC: Society for Neuroscience. http://www.sfn. org/skins/main/pdf/abstracts/am2008/poster-presentations/monday-am.pdf, Accessed on June 14, 2010.
13. Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville M, Reibaud M, Pradier L, Dunbar G, Bencherif M (2004) TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepres-sant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev 10, 147-166. (Pubitemid 38879108)
14. Gurley D, Robbins AK, Gunyuzlu PL, Moore C, Johnson EC (2008) Differential pharmacology of clin-ically relevant compounds at the two stoichiometries of the nicotinic a4b2 and a2b2 receptors. Program No. 329.9/C60, Page 172, 2008 Neuroscience Meeting Planner, Washington, DC: Society for Neuroscience. http://www.sfn. org/skins/main/pdf/abstracts/am2008/poster- presentations/monday-am.pdf, Accessed on June 14, 2010.
15. Dunbar GC, Koumenis IL, Kuchibhatla RV, Wamsley JK (2006) Evidence of efficacy for TC-1734 (AZD3480) in the treatment of cognitive impairment in older subjects. 9th Int Geneva/Springfield Symp Adv Alzheimer Ther (April 19-22, Geneva) 2006, Poster. http://media.corporate-ir.net/media-files/irol/17/178332/ GenevaPoster.pdf, Accessed on June 14, 2010.
16. Dunbar GC, Kuchibhatla R (2006) Cognitive enhancement in man with ispronicline, a nicotinic partial agonist. J Mol Neurosci30, 169-172.
17. Dunbar G, Demazieres A, Monreal A, Cisterni C, Metzger D, Kuchibhatla R, Luthringer R (2006) Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers. J Clin Pharmacol 46, 715-726. (Pubitemid 43882795)
18. Dunbar G, Boeijinga PH, Demazieres A, Cisterni C, Kuchibhatla R, Wesnes K, Luthringer R (2007) Effects of TC-1734 (AZD3480), a selective neuronal nicotinic recep-tor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology 191, 919-929. (Pubitemid 46399143)
19. Dunbar GC, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley J (2007) Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). JPsychopharmacol 21, 171-178. (Pubitemid 46280469)
20. Dunbar G, Kuchibhatla R, Lee G (2010) A randomized double-blind study comparing 25 and 50mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment. J Psychopharmacol, pub-lished online 11 June2010: 10.1177/0269881110367727.
21. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's Disease. Am J Psychiatry 141, 1356-1364.
22. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state" A practical method for grading the cognitive state of patients forthe clinician. PsychiatRes 12, 189-198.
23. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH (1977) Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alz Dis Assoc Disord 11(suppl 2), S22-S32.
24. Gauthier S, Gelinas I, Gauthier L (1997) Functional disability in Alzheimer's disease. Int Psychogeriatr 9(Suppl 1), 163-165. (Pubitemid 28045355)
25. Gelinas I, Gauthier L, McIntyre M, Gauthier S (1999) Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther53, 471-481.
26. Zarit SH (2002) Caregiver's Burden. In Family and Professional Cares: Findings Lead to Action, Andrieu S, Aquino J-P, eds. Serdi Publisher, Paris, pp. 20-24.
27. Zarit SH, Reever KE, Bach-Peterson J (1980) Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 20, 649-654.
28. Zarit S, Orr NK, Zarit JM (1985) Understanding the stress of caregivers. In The Hidden Victims of Alzheimer ' s Disease: Families UnderStress. New York University Press, New York, pp. 73-86.
29. Zarit SH, Todd PA, Zarit JM (1986) Subjective burden of husbands and wives as caregivers: alongitudinal study. Gerontologist 26, 260-266.
30. Cohen-Mansfield J, Marx MS, Rosenthal AS (1989) A description of agitation in a nursing home. J Gerontol 44 (3), M77-M84. (Pubitemid 19130580)
31. Albert SM, Castillo-Castenada C, Sano M, Jacobs DM, Marder K, Bell K, Lafleche G, Brandt J, Albert M, Stern Y (1996) Quality of life in patients with Alzheimer's disease as reported by patient proxies. J Amer Geriatrics Soc 44, 1342-1347. (Pubitemid 26374811)
32. Mohr E, Walker D, Randolph C, Sampson M, Mendis T (1996) Utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia. Int Psychogeriatr 8, 397-411. (Pubitemid 27067589)
33. Nicholl CG, Lynch S, Kelly CA, White L, Simpson L, Simpson PM, Wesnes K, Pitt BMN (1995) The Cognitive Drug Research computerised assessment system in the evalu-ation of early dementia-Is speed of the essence? Int J Geriatr Psychiatry 10, 199-206.
34. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GR (1991) The cognitive drug research computerised assessment sys-tem for demented subjects: a validation study. Int J Geriatr Psychiatry 6, 95-102.
35. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group (1998a) Donepezil improves cogni-tion and global function in Alzheimer disease. Arch Intern Med158, 1021-1031.
36. Birks J, Harvey RJ (2006) Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 1, CD001190. DOI:10.1002/14651858.CD001190. pub2 (Pubitemid 46841367)
37. Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Hunter J, Williams P (2008) Efficacy and tolerability of SB-742457, a novel 5HT6 receptor antagonist, and Donepezil in subjects with mild-to-moderate Alzheimer's disease (AD). Alzheimers Dement 4, T772-T773.
38. Gold M, Alderton C, Zvartau-Hind M, Ritchie S, Saunders A, Craft S, Landreth G, Linnamägi U, Sawchak S (2009) Effects of rosiglitazone as monotherapy in APOE4-stratified sub-jects with mild-to-moderate Alzheimer's disease. Alzheimers Dement 5, 86.
39. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group (1998b) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50, 136-145.
40. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M (2007) A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64, 1323-1329. (Pubitemid 47403089)
41. Mazzulla EC, Potter A, Wilkins H, Dunbar G, Bencherif M, Newhouse P (2009) Novel neuronal α4ß2 nicotinic agonist (AZD3480) effects on behavioral inhibition in adult ADHD. Society for NeuroScience: Annual meet-ing, Abstract 871.7/DD23 (page 771). http://www.sfn. org/skins/main/pdf/abstracts/ am2009/poster-presentations/PosterPresentation-WedPM.pdf, Accessed on June 14, 2010.